Can New Drugs Meet Lilly’s Revenue Goals If Solanezumab Fails?
New products continue to drive Lilly’s revenue growth and the company expects that to remain the case even if the final Phase III trial for Alzheimer’s candidate solanezumab fails later this year.
You may also be interested in...
The first round of biopharma earnings presentations reflects concerns about pricing and market access, which should carry over as big pharma stalwarts come center stage.
Outgoing Eli Lilly CEO and president John Lechleiter looks back over his biggest strategic decisions while at the helm of the pharma major and pinpoints some of the key navigational markers for the next phase in Lilly's lifespan.
The Phase III failure of the Alzheimer’s treatment was largely expected, but is nonetheless a disappointment for the disease and for the anti-amyloid field, casting a shadow over other therapies in development, including Lilly’s own pipeline.